Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.66 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.66 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.66 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | HBB | P68871 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.57 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.54 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3945904 | 1.00 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| SCHEMBL13301520 | 1.00 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| SCHEMBL657542 | 1.00 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| SCHEMBL13669613 | 1.00 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| SCHEMBL13822077 | 1.00 | SLC28A1 (0.66) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| Phosphoric Acid SCHEMBL3087812 | 0.94 | P2RY2 (0.62) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL28349923 | 0.93 | SLC28A1 (0.59) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| Pyrophosphoric Acid SCHEMBL3095141 | 0.90 | P2RY2 (0.67) | P2RY2P2RY14P2RY6P2RY4 | |
| SCHEMBL14929497 | 0.90 | SLC28A1 (0.57) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR | |
| SCHEMBL15059789 | 0.87 | SLC28A1 (0.58) | SLC28A1SLC28A2SLC29A1SLC28A3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110104754-A1 | CELL CULTURE MEDIUM | GENETIX LIMITED | 2011-05-05 | — | — | US | disclosed |
| EP-1818392-B1 | Cell culture medium | GENETIX LTD (GB) | 2010-08-25 | — | — | EP | disclosed |
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | BALAGURUNATHAN KUBERAN | 2010-06-10 | — | — | US | disclosed |
| WO-2008103618-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20070275988-A1 | Transition state structure and inhibitors of thymidine phosphorylases | INDUSTRIAL RESEARCH LIMITED (NZ) | 2007-11-29 | — | — | US | disclosed |
| US-20070212778-A1 | Cell culture medium | GENETIX LIMITED | 2007-09-13 | — | — | US | disclosed |
| EP-1818392-A1 | Cell culture medium | Genetix Limited (GB) | 2007-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143980-A1 | SYNTHESIS OF NOVEL XYLOSIDES AND POTENTIAL USES THEREOF | CSGALNACT1, ST3GAL3, FUT6 | SLC28A1 2894/4885SLC28A2 2542/4885SLC29A1 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.